Want to see RARE full AI Analyst Report?
RARE Stock Chart & Stats
$26.90
-$0.16(-0.59%)
At close: 4:00 PM EDT
$26.90
-$0.16(-0.59%)
Day’s Range― - ―
52-Week Range$18.29 - $39.89
Previous CloseN/A
Volume170.99K
Average Volume (3M)2.67M
Market Cap
$2.66B
Enterprise Value$4.31K
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 04, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding98,588,875
10 Day Avg. Volume1,527,664
30 Day Avg. Volume2,671,678
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.93Price Target Upside89.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.27
Revenue Forecast (FY)$748.30M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginsSustained top-line growth with very high gross margins shows the core products generate strong incremental economics. That structural margin profile means additional revenue can flow to the bottom line as operating costs are contained, supporting durable profitability potential once fixed costs are reduced.
Commercial Scale And Diversified ProductsMultiple commercial franchises and geographic penetration reduce single-product concentration risk. Rapid Evkeeza adoption and expanding patient counts across regions indicate sustainable demand, stronger payer relationships and reusable commercial infrastructure for new launches, improving long-term revenue resilience.
Credible Path To Profitability And PRV PlanA management plan that combines disciplined expense cuts, double-digit revenue growth from existing franchises and potential launches, plus monetization of priority review vouchers if approvals occur, creates a credible multi-year path to positive operating cash flow and lower reliance on equity financing.
Bears Say
Weakened Balance Sheet (negative Equity)A structurally weakened equity position reduces financial flexibility over months and years. Negative equity can constrain access to unsecured capital, increase cost of financing, and create investor and counterparty concerns, making funding strategic initiatives and launches more challenging without non-dilutive proceeds.
Persistent High Cash BurnLarge and persistent negative operating and free cash flows mean the company requires ongoing external funding or asset monetization to sustain operations. This structural cash burn elevates refinancing and dilution risk absent regulatory successes or material cost reductions, constraining strategic optionality.
Dependence On Binary Clinical/regulatory OutcomesReliance on a small set of pivotal approvals and trial readouts creates lasting execution risk: failed or ambiguous outcomes can force new studies, delay launches, increase spend and remove expected revenue/PRV proceeds. Such binary dependencies materially impact multi-quarter funding and growth plans.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?
Ultragenyx Pharmaceutical, Inc. lowest stock price was $18.29 and its highest was $39.89 in the past 12 months.
What is Ultragenyx Pharmaceutical, Inc.’s market cap?
Ultragenyx Pharmaceutical, Inc.’s market cap is $2.66B.
When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?
Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 82 days.
How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?
Ultragenyx Pharmaceutical, Inc. released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.318.
Is Ultragenyx Pharmaceutical, Inc. overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical, Inc. pay dividends?
Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.
What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?
Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -0.93.
How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?
Ultragenyx Pharmaceutical, Inc. has 98,588,875 shares outstanding.
What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?
Ultragenyx Pharmaceutical, Inc. reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -3.41%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.93 (89.33% Upside)
$50.93 (89.33% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $671.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
RARE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$50.93
▲(89.33% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.95% Insiders
19.35% Mutual Funds
5.04% Other Institutional Investors
51.90% Public Companies and Individual Investors